文献速递血栓与止血

纤连蛋白调节PF4/肝素复合物形成,并可能是降低肝素诱导的血小板减少症发生风险的因素

Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT.
PubMed 文献 · Blood · 2018-12-20

研究用洗涤血小板、富血小板血浆(PRP)、标准HIT实验室检测及物理化学方法,发现热不稳定血浆蛋白纤连蛋白以剂量依赖方式抑制PF4与血小板结合,并干扰PF4/肝素复合物形成及抗体诱导的血小板活化。在2项血清监测试验的89份血浆中,血浆纤连蛋白水平在ELISA+/SRA+/HIT+组最低,依次低于ELISA+/SRA+/HIT-组、ELISA+/SRA-/HIT-组和ELISA-/SRA-/HIT-组。提示纤连蛋白可干扰PF4/肝素复合物形成,较低纤连蛋白水平可能是PF4/肝素免疫及临床HIT突破的风险因素。

要点

  • 纤连蛋白以剂量依赖方式抑制PF4与血小板结合,在洗涤血小板体系中尤为明显。
  • 纤连蛋白可破坏PF4/肝素复合物,抑制抗体与复合物结合及抗体诱导的血小板活化。
  • 血浆纤连蛋白水平在ELISA+/SRA+/HIT+组最低,依次低于其他3组。

核心结论

  • 纤连蛋白干扰PF4/肝素复合物形成及抗PF4/肝素抗体诱导的血小板活化。
  • 洗涤血小板检测HIT敏感性高于PRP检测,部分可用纤连蛋白水平较低解释。
  • 较低血浆纤连蛋白水平可能是PF4/肝素免疫及临床HIT突破的风险因素。

研究设计与样本

  • 研究使用洗涤血小板、PRP、标准HIT实验室检测及物理化学方法。
  • 检测了来自2项血清监测试验的89份血浆。
  • 在4组呈现不同程度肝素依赖免疫及HIT表现的患者中测量纤连蛋白水平。

主要发现

  • 纤连蛋白以剂量依赖方式抑制PF4与血小板结合,洗涤血小板体系较PRP体系更明显。
  • 纤连蛋白抑制PF4/肝素与血小板结合、抗PF4/肝素抗体与PF4/肝素复合物结合及抗体诱导的血小板活化。
  • 血浆纤连蛋白水平依次为ELISA+/SRA+/HIT+组 < ELISA+/SRA+/HIT-组 ∼ ELISA+/SRA-/HIT-组 < ELISA-/SRA-/HIT-组。

关键数值与推荐

  • 血浆纤连蛋白水平在ELISA+/SRA+/HIT+组最低,依次低于ELISA+/SRA+/HIT-组、ELISA+/SRA-/HIT-组和ELISA-/SRA-/HIT-组。
  • 纤连蛋白对PF4与血小板结合的抑制呈剂量依赖方式,洗涤血小板体系较PRP体系更明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies. Platelet activation assays that use "washed" platelets are more sensitive for detecting HIT antibodies than platelet-rich plasma (PRP)-based assays. Moreover, heparin-exposed patients vary considerably with respect to the risk of PF4/heparin immunization and, among antibody-positive patients, the risk of subsequent "breakthrough" of clinical HIT with manifestation of thrombocytopenia. We used washed platelets and PRP, standard laboratory HIT tests, and physicochemical methods to identify a plasma factor interfering with PF4/heparin complexes and anti-PF4/heparin antibody-platelet interaction, thus explaining differences in functional assays. To investigate a modulating risk for PF4/heparin immunization and breakthrough of HIT, we also tested 89 plasmas from 2 serosurveillance trials. Fibronectin levels were measured in 4 patient groups exhibiting different degrees of heparin-dependent immunization and expression of HIT. The heat-labile plasma protein, fibronectin, inhibited PF4 binding to platelets in a dose-dependent fashion, particularly in washed (vs PRP) systems. Fibronectin also inhibited PF4/heparin binding to platelets, anti-PF4/heparin antibody binding to PF4/heparin complexes, and anti-PF4/heparin antibody-induced platelet activation as a result of PF4/heparin complex disruption. In addition, plasma fibronectin levels increased progressively among the following 4 patient groups: enzyme-linked immunosorbent assay (ELISA)+/serotonin-release assay (SRA)+/HIT+ < ELISA+/SRA+/HIT- ∼ ELISA+/SRA-/HIT- < ELISA-/SRA-/HIT-. Altogether, these findings suggest that fibronectin interferes with PF4/heparin complex formation and anti-PF4/heparin antibody-induced platelet activation. Reduced fibronectin levels in washed platelet assays help to explain the greater sensitivity of washed platelet (vs PRP) assays for HIT. More importantly, lower plasma fibronectin levels could represent a risk factor for PF4/heparin immunization and clinical breakthrough of HIT.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Krauel K, Preuße P, Warkentin TE, et al. Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT. Blood. 2018. PMID: 30573633. doi:10.1182/blood-2018-05-850370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。